The biotech company Pluri has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO.
The Clinical and Laboratory Standards Institute (CLSI) has implemented new Country-Based Pricing
Vetter, a globally operating contract development and manufacturing organization (CDMO), has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa recognizes the significant role that the pharmaceutical service provider plays in the field of complex injectable drugs.
Australian, European and U.S. clients are now able to tap into world-class strategic advice and full-service clinical trial capabilities following the announcement of Biointelect’s and CR2O’s new strategic partnership.
Capricorn Scientific and ExcellGene have established a strategic partnership within the biotechnology sector. Applying their collective expertise and capabilities, the collaboration seeks to help customers by optimizing processes, developing products, and offering solutions in biotechnology. The partnership is dedicated to customeroriented solutions and a commitment to excellence, with the aim of advancing biotech research, development, […]
PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, will collaborate with Sheffield Hallam University in the field of epigenetics. The partnership will focus on ‘gene-based environmental biomarkers’ – epigenetic markers – for calculating risk scores for Alzheimer’s diseases. Together with PharmaKure’s blood-based biomarker, ALZmetrix https://bitly.ws/3eZTQ, this […]
Johnson & Johnson has entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2 billion, or $1.9 billion net of estimated cash acquired.
by Dr Roopa Rao and Arden Shen The incidence of heart failure (HF) is increasing globally. Biomarkers in HF play a key role in diagnosis and prognostication. Ideal biomarkers should be easily measurable with distinct values in normal physiology, disease state and be a marker of therapeutic intervention. Several biomarkers have emerged that are potentially […]
By Dr Kyle H. Cichos and Dr Wilhelm Paulander This review examines periprosthetic joint infection (PJI) detection, highlighting the limitations of traditional methods and introducing isothermal microcalorimetry (IMC) as an innovative tool. IMC offers rapid, sensitive PJI detection, overcoming the challenges of culture-based and molecular diagnostics. Its potential applications in real-time monitoring, treatment efficacy, and […]
By Dr Seul Kee Byeon and Dr Akhilesh Pandey An elevated ratio of monolysocardiolipin to cardiolipin is a hallmark feature of Barth syndrome, a genetic disorder caused by mutations in the TAFAZZIN gene. Liquid chromatography-tandem mass spectrometry can be used as a clinical laboratory test to calculate the ratios of monolysocardiolipins to cardiolipin species for […]
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
